GlassScriptPhysician profile
Sean Forrest Pattee
NPI 1891779179
$12,799.37
in general payments reported to CMS, 2019-2025
40 companies · $2,680 in 2025
The $2,680 reported for 2025 was more than what 82% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,067 · 2020: $1,751 · 2021: $1,608 · 2022: $1,443 · 2023: $1,968 · 2024: $2,282 · 2025: $2,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,930.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,784.06 | 2019-2025 | |
| Janssen Biotech, INC. | $1,696.70 | 2020-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $1,450.59 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,016.80 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $845.60 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Ucb, INC. | $823.41 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $702.81 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $693.78 | 2019-2025 | |
| Amgen INC. | $668.02 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $629.49 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $441.46 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $369.53 | 2020-2025 | Adbry, Anzupgo |
| Pfizer INC. | $212.18 | 2019-2025 | |
| Galderma Laboratories, L.P. | $184.87 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Celgene Corporation | $151.27 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Pattee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.